DeCure's autonomous Cardio AI scientist is researching a drug-repurposing hypothesis for mitral valve disease — screening already-approved drugs against its 6-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleMitral valve disease maps to a 6-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for mitral valve disease is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
Fas associated factor 1 (FAF1) — FAF1 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet atpdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 11TA · 3.58 Å · ligand ADENOSINE-5'-TRIPHOSPHATE (ATP). Experimental structure, not a prediction.
What the evidence adds up to
Mitral valve prolapse has a strong hereditary component. Genetic studies have linked the condition to sites on chromosomes 11, 13 and 16, and identified the first mutation in familial mitral valve prolapse not related to connective tissue syndromes — an X-linked filamin A mutation. Research in a mouse Marfan model emphasises the dynamic interplay of differentiating cells and growth factors, with strong potential for therapy, according to a 2007 review. The same review stated that this new knowledge brings us closer to the ultimate goal of preventing the progression of mitral valve disease to the stage of clinical expression.
A 2014 review described myxomatous mitral valve disease as the most common form of valvular heart disease. It stated that molecular biology studies have confirmed that the myxomatous changes in mitral valve prolapse equal a cartilage phenotype, which is regulated by the Lrp5 receptor. The review noted that the timing of surgical valve repair is controversial and is the subject of a current multicentre trial, the results of which will resolve whether watchful waiting versus early surgical valve repair decreases morbidity and mortality.
A 2019 review focused on mitral regurgitation and mitral valve surgery or intervention. It discussed mitral valve anatomy, epidemiology, changes in the 2017 management guidelines, management of mitral bioprosthetic valves, transcatheter mitral valve procedures, and repair of rheumatic valves. No drug therapy for mitral valve disease was tested in any of these reviews.
What is still missing is a completed randomised trial comparing watchful waiting with early surgical repair, any drug therapy proven to alter the course of mitral valve disease in humans, and the translation of genetic and molecular findings into a treatment that prevents clinical expression of the disease.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Current Opinion in Cardiology · 2007 · 30 citations
Molecular genetics of mitral valve prolapse
AbstractPURPOSE OF REVIEW: Mitral valve prolapse is a common disorder with a strong hereditary component. It is associated with important mitral regurgitation requiring surgical repair and other clinical complications. Genetic studies can provide clues to mechanism and therapy. RECENT FINDINGS: Advances in phenotypic classification have led to linkage to sites on chromosomes 11, 13 and 16 and identification of the first mutation in familial mitral valve prolapse not related to connective tissue syndromes - an X-linked filamin A mutation. New understanding of mechanism based on studies in a mouse Marfan model emphasize the dynamic interplay of differentiating cells and growth factors, with strong potential for therapy. SUMMARY: This new knowledge brings us closer to the ultimate goal of preventing the progression of mitral valve disease to the stage of clinical expression.
Recent advances in understanding and managing mitral valve disease
AbstractInterest in the mitral valve has increased over the past few years with the development of new technologies that allow intervention in patients previously deemed too ill for treatment. This increased attention has resulted in a significant increase in publications on the mitral valve, the majority of which focus on mitral regurgitation and mitral valve surgery/intervention. The focus of this review is on publications in the past few years that offer additional insights into our understanding and management of mitral valve disease and specifically mitral regurgitation. It will discuss mitral valve anatomy, epidemiology of mitral valve disease, changes in the 2017 management guidelines, management of mitral bioprosthetic valves, transcatheter mitral valve procedures and the repair of rheumatic valves.
Expert Review of Cardiovascular Therapy · 2014 · 17 citations · open access
Myxomatous mitral valve disease bench to bedside: LDL-density-pressure regulates Lrp5
AbstractThe myxomatous mitral valve is the most common form of valvular heart disease. The pathologic presentation of myxomatous mitral valve disease varies between valve thickness, degree of leaflet prolapse and the presence or absence of flail leaflets. Recent molecular biology studies have confirmed that the myxomatous changes in mitral valve prolapse equals a cartilage phenotype, which is regulated by the Lrp5 receptor. Clinically, echocardiography defines the valve pathology to determine the surgical approach to valve repair or replacement. Furthermore, the timing of surgical valve repair is controversial and is the subject of a current multicenter trial. The results will resolve the timing of whether watchful waiting versus early surgical valve repair decreases morbidity and mortality of this disease process. This review will summarize the current understanding of the cellular and hemodynamic mechanisms of myxomatous mitral valve disease, which may have future implications in the targeted therapy of this disease process.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
